Evidence map›Paper›PMID 42741385›Full record

ArticleiScience2026

CT-based radiomics and ablation margin quantification for predicting local tumor progression in Stage I NSCLC after radiofrequency ablation.

Sibin Wang, Tianling Lyu, Zhongliang Zhang, Peng Yuan, Zenan Chen, Peng Du, Yi Zhao, Xinyuan Guo, Zichuan Jin, Yueyong Xiao and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sibin WangDepartment of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Tianling LyuAcademy for Advanced Interdisciplinary Science and Technology, Zhejiang University of Technology, Hangzhou, China.
Zhongliang ZhangDepartment of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Peng YuanKey Laboratory of New Generation Artificial Intelligence Technology and Its Interdisciplinary Applications, School of Computer Science and Engineering, Southeast University, Nanjing, China.
Zenan ChenDepartment of Ultrasound, The Fourth Affiliated Hospital, Zhejiang University School of Medicine, Yiwu, China.
Peng DuDepartment of Radiology, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.
Yi ZhaoResearch and Development Department, Zoye Corporation, Qingdao, China.
Xinyuan GuoDepartment of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Zichuan JinDepartment of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Yueyong XiaoDepartment of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.
Yang ChenKey Laboratory of New Generation Artificial Intelligence Technology and Its Interdisciplinary Applications, School of Computer Science and Engineering, Southeast University, Nanjing, China.
Xiao ZhangDepartment of Radiology, The First Medical Center of Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Local tumor progression (LTP) compromises durable local control after radiofrequency ablation (RFA) for stage I non-small cell lung cancer. We developed a three-dimensional minimum ablation margin (3D MAM) quantification workflow and evaluated its integration with post-ablation CT radiomics for individualized LTP prediction. This dual-center retrospective study included 217 patients divided into training, internal validation, and external validation cohorts. Automated segmentation, deformable image registration, and Visualization Toolkit (VTK)-based analysis enabled quantitative 3D margin assessment. An insufficient MAM (

Indexed as

computed tomographylocal tumor progressionminimum ablation marginnon-small cell lung cancerradiofrequency ablation

Identifiers

PMID42741385
PMCPMC13573749

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.